Industry Symposium: Innovative oral treatment options for patients: HR+/HER2- MBC or gBRCA-Mutated TNBC and HR+/HER2- MBC
Supported by Pfizer
Thursday, September 5, 2019
12:45-13:45
Hall B
| Innovative oral treatment options for patients: HR+/HER2- MBC or gBRCA-Mutated TNBC and HR+/HER2- MBC David C. Molthrop, USA |